comparemela.com

Latest Breaking News On - மேம்படுத்துகிறது பாதுகாப்பு - Page 8 : comparemela.com

Rental s Top 10 Stories from 2020 | For Construction Pros

This was my first piece for  Rental back in May 2020, an introduction letter to give readers more insight about who I am and my background. Looking back at that nervous new editor from seven months ago, I can’t help but smile. This change has been such a highlight of my year, and as I wrote in the piece,  “If this quarantine period has taught us anything, it’s that change can be a good thing in one way or another. I’m here to prove that to you.”   Ditch Witch shares with us a few different reasons how and why vacuum excavators are becoming more popular throughout the rental industry. Versatility and low maintenance are just two of those reasons why they re great for rental customers, and who can argue with that?  

Congress Clears Major Year-End Legislative Package Including COVID-19 Relief

Tuesday, December 22, 2020 On December 21, the Congress passed legislation providing $1.4 trillion in federal funding for Fiscal Year (FY) 2021 and approximately $900 billion for COVID-19 relief. The Consolidated Appropriations Act, 2021, which has been the subject of weeks of highly scrutinized Congressional negotiations, includes sweeping provisions that span clean energy research and development, programs focused on climate policy, energy tax extenders, pipeline safety reauthorization, water infrastructure, and language limiting surprise medical billing. At a total cost of $2.3 trillion, the 5,593-page package is the second-largest bill ever passed by Congress. Following the 2020 Presidential election, Congress returned to Washington with a substantial agenda to be addressed before wrapping up its legislative work for the 116th Congress. Federal funding had initially been extended through December 11, 2020 under a continuing resolution (CR), leaving Congress with just

U S FDA Approves Supplemental New Drug Application for Takeda s ICLUSIG® (ponatinib) for Adult Patients with Resistant or Intolerant Chronic-Phase CML

Takeda Pharmaceutical Company Limited U.S. FDA Approves Supplemental New Drug Application for Takeda’s ICLUSIG® (ponatinib) for Adult Patients with Resistant or Intolerant Chronic-Phase CML Saturday, December 19, 2020 2:19PM IST (8:49AM GMT)    – Updated ICLUSIG Label will Prove Practice-Changing, Expanding Indication to CP-CML Patients with Resistance or Intolerance to At Least Two Prior Tyrosine Kinase Inhibitors (TKIs) – ­– Approval Based on Data from the Phase 2 OPTIC Trial, Which Evaluated Response-Based ICLUSIG Dosing Regimens in CP-CML – – New Dosing Regimen in CP-CML Optimizes Benefit-Risk Profile, Providing Efficacy and Improving Safety –    Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ICLUSIG

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.